In this episode, host Shikha Jain, MD, speaks with Cyclacel CEO, Spiro Rombotis, MPH, about developing techniques and therapies for drug development, how technology has affected these advancements and more. •    Welcome to another exciting episode of Oncology Overdrive 1:15 •    About Rombotis 1:23 •    The interview 2:21     •    Can you tell us about how you ended up in the biotech and pharma spaces?  2:41 •    How did you transition to the first CEO of Cyclacel, and what has kept you in the same space for over three decades?  4:45 •    Is this how you envisioned your career? How did this vision evolve over the course of your career?  8:53 •    What does Cyclacel do, and can you describe the types of innovation you are doing there? 10:19 •    With all this new and exciting technology in the field, where do you see epigenetics and precision oncology going in the next ten to twenty years?  15:46 •    What are your thoughts on AI in the oncology space?   22:21 •    Jain and Rombotis on checks and balances when it comes to AI use in cancer care and clinical trials.   27:53 •    What’s next for you?  30:53 •    If someone could only listen to the last few minutes of this episode, what would you want them to take away? 36:18 •    How to contact Rombotis 40:25 •    Thanks for listening 40:43 Spiro Rombotis, MPH, is the CEO of Cyclacel. He has over 36 years at three public biotechs and two pharmas.

We’d love to hear from you! Send your comments/questions to Dr. Jain at [email protected]. Follow Healio on X and LinkedIn: @HemOncToday and https://www.linkedin.com/company/hemonctoday/. Follow Dr. Jain on X: @ShikhaJainMD. Rombotis can be reached via email [email protected].  Disclosures: Jain reports no relevant financial disclosures. Rombotis reports Cyclacel Ltd employment and stock ownership.